Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient

By Medioni Jacques   Cojocarasu Oana   Banu Eugeniu   Cassar-Queudeville Alexia   Halimi Philippe   Oudard Stéphane  

Targeted Oncology, Vol. 2, Iss. 3, 2007-07 ,pp. : 193-195

Springer Publishing Company

Access to resources Recommend Favorite

Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma

By Bono Petri   Rautiola Juhana   Utriainen Tapio   Joensuu Heikki  

Acta Oncologica, Vol. 50, Iss. 4, 2011-05 ,pp. : 569-573

Informa Healthcare

Access to resources Recommend Favorite

Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis

By Ibrahim Ezzeldin   Kazkaz Ghieth   Abouelkhair Khaled   Bayer Ali   Elmasri Osama  

International Journal of Clinical Oncology, Vol. 18, Iss. 6, 2013-12 ,pp. : 1060-1069

Springer Publishing Company

Access to resources Recommend Favorite

Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study

By Paglino Chiara   Imarisio Ilaria   Ganini Carlo   Morbini Patrizia   Vercelli Alessandro   Bregant Cristina   Porta Camillo  

Future Oncology, Vol. 8, Iss. 12, 2012-12 ,pp. : 1605-1612

Future Medicine

Access to resources Recommend Favorite

Health-related quality of life in Japanese patients with metastatic renal cell carcinoma treated with sunitinib

By Miyake Hideaki  

International Journal of Clinical Oncology, Vol. 18, Iss. 2, 2013-04 ,pp. : 220-225

Springer Publishing Company

Access to resources Recommend Favorite